death semaglutide Weight-Loss Drug Wegovy Slashes Risk of in Some People with Heart Disease LOWER RISK OF MACE AND

Replacing asparagine with glutamine at the 8th position might potentially reduce the risk of asparagine rearrangement and amide hydrolysis

While still emerging, this technology could eventually offer weekly or even less frequent application schedules

It may be easier to follow than medicines taken several times a day

Clinical research shows semaglutide produces average weight loss of approximately 15% at 12 months, while tirzepatide demonstrates even more dramatic results with up to 20% average weight loss in the same timeframe

A longer 52-week extension confirmed that these reductions were sustained with continued therapy (Falutz et al., JCEM 2010